Search research articles
Contact Us
Filters
Showing results (101-110 of 218) with videos related to
Page
of 22
Sort By:
International Journal of Cancer
|
May 13, 2016
Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival
Miriam Potrony, Esther Carreras, Fernando Aranda, et al.
Plos One
|
March 12, 2015
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma
Lisa Zimmer, Julia Vaubel, Peter Mohr, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2025
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy
Philipp Jansen, Wolfgang Galetzka, Carl M Thielmann, et al.
The New England Journal of Medicine
|
April 27, 2022
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab
Alexander M Menzies, Ines Pires da Silva, Claudia Trojaniello, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 5, 2023
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, et al.
Clinical and Translational Medicine
|
November 2, 2022
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype
Lea Jessica Albrecht, Anna Höwner, Klaus Griewank, et al.
Journal of Translational Medicine
|
November 7, 2015
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer, Thomas K Eigentler, Felix Kiecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition
Lisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 31, 2021
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities
Eleftheria Chorti, Sied Kebir, Misbah S Ahmed, et al.
Journal for Immunotherapy of Cancer
|
July 7, 2022
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
Ines Pires da Silva, Danny Zakria, Tasnia Ahmed, et al.
Page
of 22
Search research articles
Search
Showing results (101-110 of 218) with videos related to
Sort By:
Page
of 22
International Journal of Cancer
|
May 13, 2016
Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival
Miriam Potrony, Esther Carreras, Fernando Aranda, et al.
Plos One
|
March 12, 2015
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma
Lisa Zimmer, Julia Vaubel, Peter Mohr, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2025
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy
Philipp Jansen, Wolfgang Galetzka, Carl M Thielmann, et al.
The New England Journal of Medicine
|
April 27, 2022
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab
Alexander M Menzies, Ines Pires da Silva, Claudia Trojaniello, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 5, 2023
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, et al.
Clinical and Translational Medicine
|
November 2, 2022
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype
Lea Jessica Albrecht, Anna Höwner, Klaus Griewank, et al.
Journal of Translational Medicine
|
November 7, 2015
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer, Thomas K Eigentler, Felix Kiecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition
Lisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 31, 2021
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities
Eleftheria Chorti, Sied Kebir, Misbah S Ahmed, et al.
Journal for Immunotherapy of Cancer
|
July 7, 2022
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
Ines Pires da Silva, Danny Zakria, Tasnia Ahmed, et al.
Page
of 22